TotalMarketCap

TScan Therapeutics

TCRXNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$11.469 M

$0.18 -14.00%

Close of 6 Nov 2026

As of 6 Nov 2026, TScan Therapeutics (TCRX) has a market capitalization of $11.5M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$10.3M

#3126 by revenue

Earnings

-$129.8M

Loss-making

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #146Dyadic InternationalDYAI$13.6M
  2. #147BioCardiaBCDA$13.4M
  3. #148TScan TherapeuticsTCRX$11.5M
  4. #149Passage BIOPASG$11.1M
  5. #150Intensity TherapeuticsINTS$10.2M

What if TScan Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$444,656.57

Per share 2,462,107× higher

Bitcoin $1.53T

$24,059.59

Per share 133,220× higher

Apple $5.02T

$78,985.40

Per share 437,350× higher

Or at a round number

$20.0M$50.0M$100.0M$200.0M

Where these numbers come from

Share counts and financials for TScan Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.